Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119963 | 0.81 | DGAT1 (0.34) | DGAT1TP53RAB9ALMNA | |
| SCHEMBL28694851 | 0.81 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL4115289 | 0.75 | — | — | |
| SCHEMBL445544 | 0.75 | DGAT1 (0.39) | DGAT1TP53RAB9APKMLMNA | |
| SCHEMBL21385708 | 0.74 | — | — | |
| SCHEMBL27277889 | 0.72 | DGAT1 (0.34) | DGAT1PKM | |
| SCHEMBL10359638 | 0.71 | CYP4F2 (0.41) | DGAT1TP53RAB9ALMNAKMT2A | |
| SCHEMBL4128811 | 0.71 | TSHR (0.39) | DGAT1TP53RAB9ALMNAKMT2A | |
| SCHEMBL2015627 | 0.71 | MGAM (0.37) | DGAT1TP53RAB9APKMLMNA | |
| SCHEMBL13391665 | 0.71 | CYP4F2 (0.37) | DGAT1TP53RAB9ALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802517-B1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-12-21 | — | — | EP | disclosed |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-12 | — | — | US | disclosed |
| EP-3802517-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | Idorsia Pharmaceuticals Ltd (CH) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019234115-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-12-12 | — | — | WO | disclosed |
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD. (CN) | 2019-04-25 | — | — | US | disclosed |
| WO-2017177004-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | LPAR1, LPAR3, LPAR2 | DGAT1 820/4885TP53 4729/4885RAB9A 2340/4885 |
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | LPAR1, LPAR3, LPAR2 | DGAT1 153/4885TP53 4402/4885RAB9A 1149/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | DGAT1 322/4885TP53 4463/4885RAB9A 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.